Aktuelle Urologie · 2009
[Coincidence of adenocarcinoma and MALT lymphoma of the prostate--first report].
Клинический случайАннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uthoff D, Schmidt S, Matthies C, Tiemann M, Wagner W
Аннотация
INTRODUCTION: First description of a prostate adenocarcinoma coinciding with the rare MALT lymphoma of the prostate.
CASE REPORT: 68-year-old patient with a pT2c, pN0, M0, Gleason 3 + 3 prostate carcinoma (retropubic radical prostatectomy with pelvic lymphadenectomy) and systemic indolent MALT lymphoma of the prostate (bone marrow biopsy). Therapy and course are described and further explained by referring to case reports found in the literature. In this context, possible pathogenetic mechanisms, the prognosis for this special disease and possible therapeutic approaches are discussed.
CONCLUSION: MALT lymphomas of the prostate are rare, and so far a coincidence with a prostate carcinoma is unprecedented. The prostate carcinoma is treated according to stage, while the MALT lymphoma is managed according to individual treatment strategies. The histopathological classification is more important for the prognosis. Treatment with antibiotics to eradicate possible copathogenic Helicobacter pylori is discussed as an innovative therapeutic approach. The pathogenesis of the MALT lymphoma of the prostate cannot yet be clarified definitively according to a literature review.
CASE REPORT: 68-year-old patient with a pT2c, pN0, M0, Gleason 3 + 3 prostate carcinoma (retropubic radical prostatectomy with pelvic lymphadenectomy) and systemic indolent MALT lymphoma of the prostate (bone marrow biopsy). Therapy and course are described and further explained by referring to case reports found in the literature. In this context, possible pathogenetic mechanisms, the prognosis for this special disease and possible therapeutic approaches are discussed.
CONCLUSION: MALT lymphomas of the prostate are rare, and so far a coincidence with a prostate carcinoma is unprecedented. The prostate carcinoma is treated according to stage, while the MALT lymphoma is managed according to individual treatment strategies. The histopathological classification is more important for the prognosis. Treatment with antibiotics to eradicate possible copathogenic Helicobacter pylori is discussed as an innovative therapeutic approach. The pathogenesis of the MALT lymphoma of the prostate cannot yet be clarified definitively according to a literature review.